Blocking the progression of prostate cancer to a more aggressive form
Targeting drivers of tumor heterogeneity to block the progression to neuroendocrine prostate cancer
This study is looking at how certain features of prostate cancer can turn it into a more aggressive type called neuroendocrine prostate cancer, using special techniques to understand the genes involved, and it hopes to find new ways to treat or prevent this tougher form of cancer that could help patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10662642 on NIH RePORTER |
What this research studies
This research investigates how certain tumor characteristics in prostate cancer can lead to a more aggressive form known as neuroendocrine prostate cancer (NEPC). By using advanced genetic techniques, including CRISPR, the study aims to identify and modify specific genes that contribute to this transition. The research utilizes a unique mouse model and organoid technology to closely mimic human prostate cancer, allowing for a better understanding of how these tumors develop and respond to treatments. Patients may benefit from insights gained about potential new therapies that could prevent or treat NEPC.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with advanced prostate cancer who are experiencing treatment resistance.
Not a fit: Patients with early-stage prostate cancer or those who do not have advanced disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that prevent the progression of prostate cancer to its more aggressive neuroendocrine form.
How similar studies have performed: Other research has shown promise in targeting tumor heterogeneity in various cancers, suggesting that this approach may yield significant insights.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Brady, Nicholas James — Weill Medical Coll of Cornell Univ
- Study coordinator: Brady, Nicholas James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.